Amgen Inc. $AMGN Shares Purchased by Hofer & Associates. Inc

Key Points

• Hofer & Associates. Inc boosted its stake in Amgen by 111.4% in Q4, buying 14,302 shares to hold 27,140 shares worth about $8.88 million, making Amgen ~4.7% of its portfolio and its fifth-largest position.
• Amgen beat quarterly estimates with EPS of $5.29 (vs. $4.76 expected) and revenue of $9.87B (vs. $9.46B), set FY2026 EPS guidance of 21.600–23.000, while analysts expect roughly 20.62 EPS for the year.
• The company declared a quarterly dividend of $2.52 ($10.08 annual, yield 2.9%, ex-dividend May 15, payable June 5) and holds a consensus analyst rating of Hold with an average price target of $354.60.

Hofer & Associates. Inc boosted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 111.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,140 shares of the medical research company's stock after buying an additional 14,302 shares during the period. Amgen makes up approximately 4.7% of Hofer & Associates. Inc's portfolio, making the stock its 5th biggest position. Hofer & Associates. Inc's holdings in Amgen were worth $8,883,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of AMGN. Brighton Jones LLC lifted its holdings in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock valued at $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. increased its holdings in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock valued at $7,220,000 after purchasing an additional 5,853 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC raised its position in Amgen by 12.8% in the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 4,245 shares of the medical research company's stock valued at $1,185,000 after purchasing an additional 481 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its position in Amgen by 4.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 55,239 shares of the medical research company's stock valued at $15,423,000 after purchasing an additional 2,344 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $349.00 on Tuesday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a fifty day simple moving average of $362.96 and a two-hundred day simple moving average of $331.05. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a market cap of $188.14 billion, a price-to-earnings ratio of 24.53, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. During the same period last year, the firm earned $5.31 earnings per share. The company's revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio (DPR) is presently 70.84%.

Analysts Set New Price Targets

Several research analysts have recently commented on AMGN shares. The Goldman Sachs Group raised their price target on Amgen from $403.00 to $415.00 and gave the stock a "buy" rating in a research report on Wednesday, February 4th. Barclays initiated coverage on Amgen in a report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 price objective on the stock. Truist Financial increased their target price on Amgen from $318.00 to $319.00 and gave the stock a "hold" rating in a research note on Thursday, January 8th. Wall Street Zen downgraded Amgen from a "buy" rating to a "hold" rating in a research report on Saturday, February 21st. Finally, Wells Fargo & Company boosted their price target on shares of Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 19th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $354.60.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.